Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
THF Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
THF Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Tetrahydrofolate dehydrogenase is an enzyme of the oxidoreductase family that catalysis the reaction yielding reduce folate or Tetrahydrofolate from Dihydrofolate in cells. This Tetrahydrofolate is the substrate for purine ring synthesis, amino acid metabolism, and formation of deoxythymidine monophosphate. Tetrahydrofolate or Tetrahydro folic acid is the active form of folic acid. Folic acid is essential for the synthesis of RBCs and for maintaining brain health. THF dehydrogenase inhibitors block this pathway by acting on the enzyme THF dehydrogenase. These are used in treating many diseases like Rheumatoid Arthritis, Malaria, Traveller’s diarrhea, various types of cancers like breast cancer and non-Hodgkin’s lymphoma, and others in which the formation of folic acid or RBCs is involved. Businesses are looking for new and innovative chemicals to treat and prevent these diseases. Over the upcoming years, the market for THF dehydrogenase Inhibitors will witness significantly increased revenue due to the development and introduction of fresh products by industry participants. According to WHO, there were 247 million cases of malaria globally in 2021 as compared to 245 million patients in 2020. According to the Centers for Disease Control and Prevention (CDC), the highest malaria prevalence is in Africa. Developed nations have controlled the spread of malaria due to better health infrastructure and public health education but are at some risk of getting it back if held loose. Several of these inhibitors are on the market, while many are in ongoing clinical trials. 18 companies have various products in their pipelines, with 20 products in various stages of clinical trials. 1 product is in Phase 4, 6 products are in Phase 3, 7 products are in Phase 2, and 2 products are in Phase 1 of the clinical trials.
Key Developments of THF Dehydrogenase Inhibitors
Approved molecules
Drugs in Pipeline
Clinical Activity and Developments of THF Dehydrogenase Inhibitors
|
Molecule name |
Number of studies |
|
Folotyn (pralatrexate) |
37 |
|
Pemfexy (pemetrexed) |
25 |
|
Neutrexin (trimetrexate) |
17 |
|
Otrexup (methotrexate) |
14 |
|
Metoject (methotrexate autopen) |
11 |
Drugs like Metoject (Methotrexate autopen) and Folotyn (pralatrexate) are commercially available THF dehydrogenase Inhibitors in the market and are used to treat various indications. Methotrexate is used for indications like Rheumatoid Arthritis, juvenile idiopathic arthritis, psoriasis, and various types of cancers like breast cancer, non-Hodgkin’s lymphoma and Crohn’s disease. Folotyn is an anti-neoplastic agent ad is used in the treatment of relapsed or refractory peripheral T-cell lymphoma. According to The Arthritis Foundation, the global prevalence of Rheumatoid Arthritis (RA) in developed countries is 0.5% to 1% with around 1.3 million people suffering from it in the USA in 2022. An increase in the incidence of RA is expected to create an opportunity and be a growth driver for the THF dehydrogenase Inhibitor market.
According to a research article in 2020, the global prevalence of RA was about 1%, while in Europe, it differs according to geography and latitude. Countries like Sweden and Germany had a prevalence of 0.65%, while France and Italy had a lower prevalence than the global estimate of 0.19% and 0.41%, respectively. Several factors, such as Gender and environmental factors, also contribute to the variability in the prevalence rates. Breast cancer accounted for 13.3% of the new cases in Europe in 2020, with an estimated incidence of 576,300. According to CDC, every year in the USA, an estimated 264,000 breast cancer cases are diagnosed in women and about 2,400 in men.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Metoject (methotrexate autopen) and generic drugs like Methotrexate, Pemetrexed, Dapsone, and Atovaquone are some of the THF dehydrogenase Inhibitors approved by the FDA.
These are being used in various indications like Rheumatoid Arthritis, Malaria, Traveller’s diarrhea, multiple types of cancers like breast cancer and non-Hodgkin’s lymphoma, and others.
Nippon Medac, Aurobindo, Eagle Pharma, Pfizer, and Antares are some of the major market players for THF dehydrogenase Inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market and changing lifestyles leading to various types of cancers, and increasing incidence of RA are the key opportunities for THF dehydrogenase Inhibitors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.